Difference between revisions of "Offermann A, et al. Oncotarget (2017) cited as Ref 363 in DOI: 10.1038/s41392-020-0110-5 (Q9626)"
Jump to navigation
Jump to search
(Created claim: Published In Name String (P102): Oncotarget, #quickstatements; #temporary_batch_1590006349955) |
(Created claim: Page(s) (P105): 7964-7976, #quickstatements; #temporary_batch_1590074839150) |
||
(2 intermediate revisions by the same user not shown) | |||
Property / Volume | |||
+ | 8 | ||
Property / Volume: 8 / rank | |||
+ | Normal rank | ||
Property / title | |||
+ | MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling (English) | ||
Property / title: MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling (English) / rank | |||
+ | Normal rank | ||
Property / Page(s) | |||
+ | 7964-7976 | ||
Property / Page(s): 7964-7976 / rank | |||
+ | Normal rank |
Latest revision as of 15:39, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language | Label | Description | Also known as |
---|---|---|---|
English |
Offermann A, et al. Oncotarget (2017) cited as Ref 363 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Offermann A
0 references
2017
0 references
Oncotarget
0 references
8
0 references
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling (English)
0 references
7964-7976
0 references